← 返回

为髓系细胞靶向免疫治疗照亮前路

英文原题:Shining a LIGHT on myeloid cell targeted immunotherapy.

查看英文原题

Shining a LIGHT on myeloid cell targeted immunotherapy.

PubMed 2023/04/05(内容时间) Eur J Cancer Q1 · IF 7.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

尽管已有十多年的临床试验将新兴检查点抑制与PD-1/L1抑制剂骨架联合使用,但在PD-1/L1抑制剂耐药或难治性实体瘤中,尤其是在以骨髓抑制性微环境为主的肿瘤中,尚未显示出有意义的生存获益。

因此,要实现持久抗肿瘤免疫,可能需要联合适应性和先天性免疫刺激、髓系细胞重极化、增强APC激活和抗原加工/呈递、解除CD47/SIRPα(分化簇47/信号调节蛋白α)的“别吃我”信号、提供凋亡性“促吃我”或“找到我”信号,以及阻断免疫检查点。鉴于髓系细胞在大多数实体瘤的肿瘤微环境中含量丰富,近期已强调有效靶向mLILRB2和SIRPA髓系细胞以提高缓解率的重要性。TNFSF14,即LIGHT,是一种肿瘤坏死超家族配体,具有广泛的适应性和先天性免疫活性,包括(1)通过淋巴毒素β受体(LTβR)激活髓系细胞,(2)通过疱疹病毒侵入介体(HVEM)诱导T/NK(T细胞和NK 细胞)抗肿瘤免疫活性,(3)通过肿瘤基质细胞上的LTβR增强促炎细胞因子/趋化因子分泌,(4)在体外直接诱导肿瘤细胞凋亡,以及(5)通过促进高内皮微静脉(HEV)形成和诱导三级淋巴结构,重组淋巴组织结构,包括在肿瘤微环境(TME)内。LTBR(淋巴毒素β受体)和HVEM在实体瘤中的一系列共刺激受体中排名靠前,这引发了人们对LIGHT介导的共刺激可能如何区别于越来越多未能作为单药或与PD-1抑制剂联合提供生存获益的免疫治疗靶点的兴趣,尤其是在检查点获得性耐药的情况下。

展开英文摘要原文

Despite over a decade of clinical trials combining inhibition of emerging checkpoints with a PD-1/L1 inhibitor backbone, meaningful survival benefits have not been shown in PD-1/L1 inhibitor resistant or refractory solid tumours, particularly tumours dominated by a myelosuppressive microenvironment. Achieving durable anti-tumour immunity will therefore likely require combination of adaptive and innate immune stimulation, myeloid repolarisation, enhanced APC activation and antigen processing/presentation, lifting of the CD47/SIRPα (Cluster of Differentiation 47/signal regulatory protein alpha) 'do not eat me' signal, provision of an apoptotic 'pro-eat me' or 'find me' signal, and blockade of immune checkpoints. The importance of effectively targeting mLILRB2 and SIRPAyeloid cells to achieve improved response rates has recently been emphasised, given myeloid cells are abundant in the tumour microenvironment of most solid tumours.

TNFSF14, or LIGHT, is a tumour necrosis superfamily ligand with a broad range of adaptive and innate immune activities, including (1) myeloid cell activation through Lymphotoxin Beta Receptor (LTβR), (2) T/NK (T cell and natural killer cell) induced anti-tumour immune activity through Herpes virus entry mediator (HVEM), (3) potentiation of proinflammatory cytokine/chemokine secretion through LTβR on tumour stromal cells, (4) direct induction of tumour cell apoptosis in vitro, and (5) the reorganisation of lymphatic tissue architecture, including within the tumour microenvironment (TME), by promoting high endothelial venule (HEV) formation and induction of tertiary lymphoid structures.

LTBR (Lymphotoxin beta receptor) and HVEM rank highly amongst a range of costimulatory receptors in solid tumours, which raises interest in considering how LIGHT-mediated costimulation may be distinct from a growing list of immunotherapy targets which have failed to provide survival benefit as monotherapy or in combination with PD-1 inhibitors, particularly in the checkpoint acquired resistant setting.

论文信息

作者
Shuptrine CW、Perez VM、Selitsky SR、Schreiber TH、Fromm G
第一作者单位
Shattuck Labs Inc., Austin, TX, USA; Shattuck Labs Inc., Durham, NC, USA.United States
通讯作者单位
Shattuck Labs Inc., Austin, TX, USA; Shattuck Labs Inc., Durham, NC, USA. Electronic address: gfromm@shattucklabs.com.United States
文献类型
综述 · 非美国政府资助研究
期刊
European journal of cancer (Oxford, England : 1990)2023 Jul
原文标识
PubMed 37167762 · DOI 10.1016/j.ejca.2023.03.040